Unknown

Dataset Information

0

Antiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice.


ABSTRACT: Gastrointestinal peptides such as peptide YY (PYY) can regulate appetite, which is relevant to the study of obesity. The intraperitoneal bolus administration of PYY3-36 and a 12-amino acid PYY analogue, benzoyl-[Cha27,28,36,Aib31]PYY25-36 (1), showed similar anorectic activity by activating the Y2 receptor (Y2R). However, food intake inhibition and body weight loss were not observed upon continuous subcutaneous administration of 1 with osmotic pumps in diet-induced obese (DIO) mice. N-Terminal elongation of 1, together with amino acid substitution at position 24, led to a hydrophilic 14-amino acid peptide, Ac-[d-Hyp24,Cha27,28,36,Aib31]PYY23-36 (18), that showed higher affinity and more potent agonist activity for Y2R and a robust anorectic activity with potency similar to that of PYY3-36. In addition, the continuous subcutaneous administration of 18 at 0.3 mg/(kg·day) induced significant body weight loss in DIO mice. These results suggest that a short-length PYY analogue can be a lead compound for antiobesity therapy in a sustained-release formulation.

SUBMITTER: Nishizawa N 

PROVIDER: S-EPMC5467190 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice.

Nishizawa Naoki N   Niida Ayumu A   Masuda Yasushi Y   Kumano Satoshi S   Yokoyama Kotaro K   Hirabayashi Hideki H   Amano Nobuyuki N   Ohtaki Tetsuya T   Asami Taiji T  

ACS medicinal chemistry letters 20170501 6


Gastrointestinal peptides such as peptide YY (PYY) can regulate appetite, which is relevant to the study of obesity. The intraperitoneal bolus administration of PYY<sub>3-36</sub> and a 12-amino acid PYY analogue, benzoyl-[Cha<sup>27,28,36</sup>,Aib<sup>31</sup>]PYY<sub>25-36</sub> (<b>1</b>), showed similar anorectic activity by activating the Y2 receptor (Y2R). However, food intake inhibition and body weight loss were not observed upon continuous subcutaneous administration of <b>1</b> with os  ...[more]

Similar Datasets

| S-EPMC6044503 | biostudies-literature
| S-EPMC2806102 | biostudies-literature
| S-EPMC3391226 | biostudies-literature
2024-02-28 | GSE229566 | GEO
| S-EPMC6096978 | biostudies-literature
| S-EPMC4914964 | biostudies-literature
| S-EPMC6608564 | biostudies-literature
| S-EPMC3834777 | biostudies-literature
| S-EPMC5654385 | biostudies-literature
| S-EPMC3570948 | biostudies-literature